Hämatologie

Die akute myeloische Leukämie (AML) ist eine vorwiegend im höheren Lebensalter diagnostizierte bösartige Erkrankung des blutbildenden Systems. Wir forschen intensiv an der Therapie dieser aggressiv verlaufenden Leukämie.

Ansprechpartner

Univ.-Prof. Dr.
Heinz Sill 
T: +43 316 385 80257

Forschung

Unsere Ziele

  • Neue pathogenetische Mechanismen bei AML und anderen myeloischen Neoplasmen zu  identifizieren.
  • Mechanismen der myeloischen Leukämogenese zu verstehe.
  • Neuartige Leukämietherapien zu identifizieren.
Ziele

Unser Forschungsansatz

Zusätzlich zur Grundlagenforschung führen wir eine Reihe klinischer Studien durch, die Patient*innen mit myeloischen Erkrankungen den Zugang zu innovativen Arzneimitteln und therapeutischen Ansätzen ermöglichen.

 

Teams

Team Sill

Team Wölfler

Team Reinisch

Vernetzung

Kooperationspartner*innen

  • German-Austrian AML Study Group, University Hospital Ulm, Ulm, Germany
  • Study Alliance Leukemia, University Hospital Carl Gustav Carus, Dresden, Germany
  • Daniel Swarovski Research Laboratory, Medical University of Innsbruck, Innsbruck, Austria
  • Systems Biology Ireland, Conway Institute, University College Dublin
  • Department of Hematology, Erasmus University Medical Center, Rotterdam, NL
  • The Beatson Institute for Cancer Research, Cancer Research UK, Glasgow, UK
  • Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA

Klinische Studien

Acute myeloid leukemia

  • AMLSG 21-13: Randomized phase III study of intensive chemotherapy with or without dasatinib (Sprycel™) in adult patients with newly diagnosed core-binding factor acute myeloid leukemia (CBF-AML)
  • ARMADA2000/AML003: Phase III multicenter open-label randomized trial to evaluate efficacy and safety of CPI-613® (devimistat) in combination with high dose cytarabine and mitoxantrone (CHAM) compared to high dose cytarabine and mitoxantrone (HAM) therapy and control sub-groups: combination of mitoxantrone, etoposide and cytarabine (MEC) and combination of fludarabine, cytarabine, and filgrastim (FLAG) in older patients (≥ 50 years) with relapsed/refractory acute myeloid leukemia (AML)
  • AMLSG BiO: Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leukämie
  • AMLSG 30-18: Randomized phase III study of standard intensive chemotherapy versus Intensive chemotherapy with CPX-351 in adult patients with newly diagnosed AML and intermediate- or adverse genetics
  • AMLSG 29-18: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of AG-120 or AG-221 in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy
  • AMLSG 28-18: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Myelodysplastic Syndromes

  • STIMULUS-MDS2: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or chronic myelomonocytic leukemia-2 (CMML-2)

Myeloproliferative Neoplasms

  • PASS     A prospective, multicenter, non-interventional, observational, post-authorization safety study of ropeginterferon alfa-2b in polycythaemia vera patients
  • TRANSFORM-1: A randomized, double-blind, placebo-controlled, phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib in subjects with myelofibrosis (TRANSFORM-1)
  • TRANSFORM-2: A randomized, open-label, phase 3, study evaluating efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in subjects with relapsed/ refractory myelofibrosis (TRANSFORM-2)
  • FREEDOM2: A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (dynamic international prognostic scoring system)-intermediate or high risk primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib.
  • MANIFEST-2: A phase 3 study of CPI-0610, a small molecule inhibitor of BETA phase 3 study of CPI-0610, a small molecule inhibitor of BET proteins, in patients with myelofibrosis
  • Independence: A phase 3, double-blind, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with myeloproliferative neoplasm-associated myelofibrosis on concomitant JAK2 inhibitor therapy and who require red blood cell transfusions
  • GIVE-IN: Phase 3 study to assess the efficacy and safety of givinostat versus hydroxyurea in JAK2V617F-positive high-risk polycythemia vera patients: the GIVE-IN PV TRIAL